Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone) for the prevention of malaria

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
K C Kain

Abstract

Each year at least 30 000 Western travellers acquire malaria and approximately 1-4% of those who acquire Plasmodium falciparum malaria will die as a result of infection. Almost all cases and fatalities are preventable with the use of measures to reduce mosquito bites and appropriate chemoprophylaxis for those at high risk of infection. There are currently a limited number of licensed drugs available to prevent malaria in travellers. New effective and well tolerated agents are urgently needed because of increasing resistance to antimalarials such as chloroquine and proguanil, and real and perceived intolerance to standard drugs such as mefloquine. A newly licensed antimalarial (atovaquone plus proguanil; Malarone) compares favourably with other drug options, although some prescribers may be unfamiliar with the specific advantages and disadvantages of this antimalarial. This article reviews recent clinical experience and randomised controlled trial data in order to address frequently asked questions about this new combination drug.

References

Aug 15, 1990·Annals of Internal Medicine·A E Greenberg, H O Lobel
Sep 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J SotoJ Berman
Jan 1, 1996·Clinical Pharmacology and Therapeutics·B L LeeH F Chambers
Nov 1, 1996·Transactions of the Royal Society of Tropical Medicine and Hygiene·D R HillD J Bradley
Oct 14, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G D ShanksT R Scott
May 27, 1999·The American Journal of Tropical Medicine and Hygiene·T A ShapiroP Barditch-Crovo
May 29, 1999·Antimicrobial Agents and Chemotherapy·I K Srivastava, A B Vaidya
Jun 8, 2000·The New England Journal of Medicine·E T Ryan, K C Kain
Mar 17, 2001·The Journal of Antimicrobial Chemotherapy·F BarchiesiM A Viviani
Jun 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K C KainJ S Keystone
Jul 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G D ShanksJ S Keystone
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D OverboschUNKNOWN Malarone International Study Team
Oct 3, 2001·Transactions of the Royal Society of Tropical Medicine and Hygiene·J D BermanM J Shmuklarsky
Jul 5, 2002·The New England Journal of Medicine·Mark S Fradin, John F Day
Aug 16, 2002·The New England Journal of Medicine·Edward T RyanKevin C Kain
Sep 14, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Judith LingUNKNOWN Naval Medical Research Unit 2 Clinical Trial Team
Nov 1, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean-François FaucherPeter G Kremsner
Dec 10, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michèle van VugtFrançois Nosten
Mar 13, 2003·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·D.J. BradleyJ Williams

❮ Previous
Next ❯

Citations

Mar 24, 2006·Tropical Medicine & International Health : TM & IH·V WisemanW Stevens
Aug 8, 2021·European Journal of Medicinal Chemistry·Oleksandr GrytsaiRachid Benhida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

American Journal of Clinical Oncology
Glenn LiuJames P Thomas
Current Infectious Disease Reports
Kathryn N. Suh, J S Keystone
BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
J N Zuckerman
Air Medical Journal
N J Lathrop, M Lentz
© 2022 Meta ULC. All rights reserved